Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations

References

• Statins for millions more? Lancet. 2014;383:669.
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. American College of Cardiology/American Heart Association task force on practice guidelines, 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;63:2889–2934.
   PubMed Web of Science ®Google Scholar
• Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532–2561.
   PubMed Web of Science ®Google Scholar
• Fernandez G, Spatz ES, Jablecki C, et al. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med. 2011;78:393–403.
   PubMedGoogle Scholar
• Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J. 2014;168:6–15.
   PubMed Web of Science ®Google Scholar
• Mancini GB, Baker S, Bergeron J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Consensus Working Group update. Can J Cardiol. 2016;32(7 Suppl):S35–65.
   PubMed Web of Science ®Google Scholar
• Pasternak RC, Smith SC Jr., Bairey Merz CN, et al. American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute, ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002;40:56.
   PubMedGoogle Scholar
• Stroes ES, Thompson PD, Corsini A, et al. European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel statement on assessment, aetiology and management. Eur Heart J. 2015;36:1012–1022.
   PubMed Web of Science ®Google Scholar
• Link E, Parish S, Armitage J, et al.; SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy genome wide study. N Engl J Med. 2008;359:789–799.
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Baker SK, Jacobson TA, et al. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8:S58–71.
   PubMed Web of Science ®Google Scholar
• Mohassel P, Mammen AL. The spectrum of statin myopathy. Curr Opin Rheumatol. 2013;25:747–752.
   PubMed Web of Science ®Google Scholar
• Alfirevic A, Neely D, Armitage J, et al. Phenotype standardization for statin-induced myotoxicity. Clin Pharmacol Ther. 2014;96:470–476.
   PubMed Web of Science ®Google Scholar
• Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97:52C–60C.
   PubMed Web of Science ®Google Scholar
• Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl JmMed. 2009;361:62–72.
   PubMed Web of Science ®Google Scholar
• Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;CD004816.
   PubMed Web of Science ®Google Scholar
• Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403–414.
   PubMed Web of Science ®Google Scholar
• El-Salem K, Ababneh B, Rudnicki S, et al. Prevalence and risk factors of muscle complications secondary to statins. Muscle Nerve. 2011;44:877–881.
   PubMed Web of Science ®Google Scholar
• Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. Circulation. 2013;127:96–103.
   PubMed Web of Science ®Google Scholar
• Gupta A, Thompson D, Whitehouse A, et al.; ASCOT Investigators. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet. 2017 Jun;24(389):2473–2481.
   Google Scholar
• Hansen KE, Hildebrand JP, Ferguson EE, et al. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med. 2005;165:2671–2676.
   PubMed Web of Science ®Google Scholar
• Armour R, Zhou L. Outcomes of statin myopathy after statin withdrawal. J Clin Neuromuscul Dis. 2013;14:103–109.
   PubMedGoogle Scholar
• Selva-O’Callaghan A, Alvarado-Cardenas M, Marin A, et al. Statins and myositis: the role of anti-HMGCR antibodies. Expert Rev Clin Immunol. 2015;11:1277–1279.
   PubMed Web of Science ®Google Scholar
• Floyd JS, Brody JA, Tiniakou E, et al. Absence of anti-HMG-CoA reductase autoantibodies in severe self-limited statin-related myopathy. Muscle Nerve. 2016;54:142–144.
   PubMed Web of Science ®Google Scholar
• Christopher-Stine L, Casciola-Rosen LA, Hong G, et al. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum. 2010;62:2757–2766.
   PubMed Web of Science ®Google Scholar
• Nazir S, Lohani S, Tachamo N, et al. Statin-associated autoimmune myopathy: a systematic review of 100 cases. J Clin Rheumatol. 2017;23:149–154.
   PubMed Web of Science ®Google Scholar
• Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63:713–721.
   PubMed Web of Science ®Google Scholar
• Kennedy N, Keating P, O’Donnell J. HMGCR-associated myositis: a New Zealand case series and estimate of incidence. Intern Med J. 2016;46:622–625.
   PubMed Web of Science ®Google Scholar
• Alvarado-Cardenas M, Marin-Sánchez A, Martínez MA, et al. Statin-associated autoimmune myopathy: a distinct new IFL pattern can increase the rate of HMGCR antibody detection by clinical laboratories. Autoimmun Rev. 2016;15:1161–1166.
   PubMed Web of Science ®Google Scholar
• Ge Y, Lu X, Peng Q, et al. Clinical characteristics of anti-3-hydroxy-3-methylglutaryl coenzyme a reductase antibodies in Chinese patients with idiopathic inflammatory myopathies. PLoS One. 2015;10:e0141616.
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Suzuki S, Nishimura H, et al. Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies: an observational study in Japan. Medicine (Baltimore). 2015;94:e416.
   PubMed Web of Science ®Google Scholar
• Limaye V, Bundell C, Hollingsworth P, et al. Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy. Muscle Nerve. 2015;52:196–203.
   PubMed Web of Science ®Google Scholar
• Allenbach Y, Drouot L, Rigolet A, et al. French Myositis Network. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore). 2014;93:150–157.
   PubMed Web of Science ®Google Scholar
• Mammen AL. Statin-associated autoimmune myopathy. N Engl J Med. 2016;374:664–669.
   PubMed Web of Science ®Google Scholar
• Kishi T, Rider LG, Pak K, et al.; Childhood Myositis Heterogeneity Study Group. Association of anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase autoantibodies with DRB1*07:01 and severe myositis in juvenile myositis patients. Arthritis Care Res (Hoboken). 2017;69:1088–1094.
   PubMed Web of Science ®Google Scholar
• Mammen AL, Gaudet D, Brisson D, et al. Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Care Res (Hoboken). 2012;64:1233–1237.
   PubMed Web of Science ®Google Scholar
• Mammen AL, Pak K, Williams EK, et al. Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res (Hoboken). 2012;64:269–272.
   PubMed Web of Science ®Google Scholar
• Musset L, Miyara M, Benveniste O, et al. Analysis of autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme A reductase using different technologies. J Immunol Res. 2014;2014:405956.
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993–2000.
   PubMed Web of Science ®Google Scholar
• Mammen AL, Tiniakou E. Intravenous immune globulin for statin-triggered autoimmune myopathy. N Engl J Med. 2015 Oct;373:1680–1682.
   PubMed Web of Science ®Google Scholar
• Komai E, Takemoto M, Yokote K. Atorvastatin-induced dermatomyositis in a 47-year-old woman with Sjogren’s syndrome. Acta Cardiol. 2015;70:373.
   PubMed Web of Science ®Google Scholar
• Giordano N, Senesi M, Mattii G, et al. Polymyositis associated with simvastatin. Lancet. 1997;349:1600–1601.
   PubMed Web of Science ®Google Scholar
• Noel B, Cerottini JP, Panizzon RG. Atorvastatin-induced dermatomyositis. Am J Med. 2001;110:670–671.
   PubMed Web of Science ®Google Scholar
• Wu Y, Lach B, Provias JP, et al. Statin-associated autoimmune myopathies: a pathophysiologic spectrum. Can J Neurol Sci. 2014;41:638–647.
   PubMed Web of Science ®Google Scholar
• Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain. 2016;139:2131–2135.
   PubMed Web of Science ®Google Scholar
• Kadoya M, Hida A, Hashimoto Maeda M, et al. Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy. Neurol Neuroimmunol Neuroinflamm. 2016;3:e290.
   PubMed Web of Science ®Google Scholar
• Tiniakou E, Pinal-Fernandez I, Lloyd TE, et al. More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Rheumatology (Oxford). 2017;56:787–794.
   PubMed Web of Science ®Google Scholar
• Tansley SL, Betteridge ZE, Simou S, et al.; Juvenile Dermatomyositis Research Group. Anti-HMGCR autoantibodies in juvenile idiopathic inflammatory myopathies identify a rare but clinically important subset of patients. J Rheumatol. 2017;44:488–492.
   PubMed Web of Science ®Google Scholar
• Liang WC, Uruha A, Suzuki S, et al. Pediatric necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies. Rheumatology (Oxford). 2017;56:287–293.
   PubMed Web of Science ®Google Scholar
• Sakamoto K, Kimura J. Mechanism of statin-induced rhabdomyolysis. J Pharmacol Sci. 2013;123:289–294.
   PubMed Web of Science ®Google Scholar
• Ramachandran R, Wierzbicki AS. Statins, muscle disease and mitochondria. J Clin Med. 2017;6(8):pii: E75.
   PubMed Web of Science ®Google Scholar
• Backes JM, Ruisinger JF, Gibson CA, et al. Statin-associated muscle symptoms-managing the highly intolerant. J Clin Lipidol. 2017;11:24–33.
   PubMed Web of Science ®Google Scholar
• Taylor BA, Thompson PD. Muscle-related side-effects of statins: from mechanisms to evidence-based solutions. Curr Opin Lipidol. 2015;26:221–227.
   PubMed Web of Science ®Google Scholar
• Patel J, Superko HR, Martin SS, et al. Genetic and immunologic susceptibility to statin-related myopathy. Atherosclerosis. 2015;240:260–271.
   PubMed Web of Science ®Google Scholar
• Trapani L, Segatto M, La Rosa P, et al. 3-Hydroxy 3-methylglutaryl coenzyme A reductase inhibition impairs muscle regeneration. J Cell Biochem. 2012;113:2057–2063.
   PubMed Web of Science ®Google Scholar
• Martini C, Trapani L, Narciso L, et al. 3-Hydroxy 3-methylglutaryl coenzyme A reductase increase is essential for rat muscle differentiation. J Cell Physiol. 2009;220:524–530.
   PubMed Web of Science ®Google Scholar
• Werner JL, Christopher-Stine L, Ghazarian SR, et al. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum. 2012;64:4087–4093.
   PubMed Web of Science ®Google Scholar
• Arouche-Delaperche L, Allenbach Y, Amelin D, et al. Pathogenic role of antisignal recognition protein and anti-3-hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies. Ann Neurol. 2017;81:538–548.
   PubMed Web of Science ®Google Scholar
• Wang TH, Lin TF. Monascus rice products. Adv Food Nutr Res. 2007;53:123–159.
   PubMedGoogle Scholar
• Zhao ZJ, Pan YZ, Liu QJ, et al. Exposure assessment of lovastatin in Pu-erh tea. Int J Food Microbiol. 2013;164:26–31.
   PubMed Web of Science ®Google Scholar
• Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot (Tokyo). 1976;29:1346–1348.
   PubMed Web of Science ®Google Scholar
• Pelli N, Setti M, Ceppa P, et al. Autoimmune hepatitis revealed by atorvastatin. Eur J Gastroenterol Hepatol. 2003;15:921–924.
   PubMed Web of Science ®Google Scholar
• Wolters LM, Van Buuren HR. Rosuvastatin-associated hepatitis with autoimmune features. Eur J Gastroenterol Hepatol. 2005;17:589–590.
   PubMed Web of Science ®Google Scholar
• Alvarado Cárdenas M, Marín Sánchez A, Lima Ruiz J. Statins and autoimmunity. Med Clin (Barc). 2015;145:399–403.
   PubMed Web of Science ®Google Scholar
• Russo MW, Hoofnagle JH, Gu J, et al. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology. 2014;60:679–686.
   PubMed Web of Science ®Google Scholar
• Palamuthusingam D, Mantha M, Dheda S. HMG CoA reductase inhibitor associated myositis and autoimmune hepatitis. Intern Med J. 2017;47:1213–1215.
   PubMed Web of Science ®Google Scholar
• Dullaart RPF. PCSK9 inhibition to reduce cardiovascular events. N Engl J Med. 2017;376:1790–1791.
   PubMed Web of Science ®Google Scholar